Search results for: 'coupler therapies'

Frost & Sullivan has recently completed a comprehensive analysis on the current and future strategic imperatives of game-changing Asia-Pacific (APAC) pharmaceutical companies. The analysis primarily focuses on the changing trends in the pharmaceutical industry with respect to drug research and development, manufacturing, supply chain, and marketing...

02 Aug 2019  |  Asia Pacific  |  Market Research

Strategic Analysis of the Electric Vehicle Charging Infrastructure in China, 2018–2025

With the Increase in the Number of Electric Vehicles, Public Charging Points in Operation are Likely to Reach 4 Million Units by 2025

Infographics

×

Key Issues Addressed Key Benefits

About 1.05 million units of electric vehicles (EVs) were sold in China in 2018. Battery electric vehicle (BEV) segment dominated the Chinese EV market with a 74.8% share, or sales of 788,000 units, in the year. The country is implementing the China V emission standard. Shanghai and Guangzhou are likely to pioneer the upgrade to the China VIB standa...

05 Apr 2023  |  Asia Pacific  |  Market Outlook

Asia-Pacific Pharmaceutical Industry Outlook, 2023

Disruptive Technology Adoption and Outsourcing Growth is Advancing Innovation in the Pharmaceutical Industry

Infographics

×

Asia-Pacific’s pharmaceutical market is forecast to record 4.2% growth from 2022 to 2027, with China and Japan dominating the market in terms of value. Generics dominate the regional markets based on volume, directly impacting innovator molecule uptake. Nevertheless, Asia-Pacific is establishing itself as a global innovation hub, with China, Japan,...

A market outlook of the Cardiac Rhythm Management Devices covering China, Hong Kong, South Korea and Malaysia. This study includes the market drivers, restraints and forecasting for the pacemaker, implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices and CRM leads. The forecast period of the study is from 2...

This study presents an overview of the Asia-Pacific infectious disease point-of-care testing (POCT) market with an emphasis on some of the key trends and growth opportunities that are shaping the market. The study highlights some of the emerging business models supporting the development and adoption of innovative diagnostic tests. The Asia-Pacif...

10 Jan 2018  |  Asia Pacific  |  Market Research

APAC Biosimilar Market, Forecast 2025

Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth

Infographics

×

Key Issues Addressed Key Benefits

Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Korea, o...

23 Mar 2017  |  Asia Pacific  |  Market Research

APAC Molecular Diagnostics Market, Forecast to 2021

Pharmerging Economies with Rising Healthcare Demands will Accentuate Growth

Infographics

×

The molecular diagnostics (MDx) market in APAC is witnessing rapid growth due to two main factors: the high adoption of MDx tests for infectious diseases applications in emerging countries, and the advent of innovative diagnostic solutions in cancer and NGS based solutions that are gaining pace in Asia. Multinational companies have not only identif...

This research deliverable provides deep insights into the clinical development and outsourcing market in India. It also includes an overview of the Indian regulatory and R&D process briefing about the clinical trials registration process, trends in regional/local pharmaceutical and biotechnology development as well as the impact of those developmen...

24 Feb 2015  |  Asia Pacific  |  Market Research

Analysis of the Global Oncology Drug Delivery Market

Future Impact of Emerging Technologies

Infographics

×

The global oncology drug delivery market (or oncolytics market) was worth $91.00 billion in 2013 and has been growing at an annual rate of 5.0%. The market, which includes drug delivery systems for cancer therapy and cancer pain, is expected to generate $100.96 billion in 2015. The oral drug delivery systems segment accounted for an estimated 25.0%...